Definium Therapeutics Doses First Patient in Second Phase 3 Study for Major Depressive Disorder

summarizeSummary

Definium Therapeutics announced the dosing of the first patient in Ascend, its second Phase 3 pivotal study for DT120 ODT in Major Depressive Disorder, signaling significant progress in its clinical pipeline.

check_boxKey Events

• Second Phase 3 Study Initiated

  Definium Therapeutics has dosed the first patient in Ascend, its second Phase 3 pivotal study evaluating DT120 ODT for the treatment of Major Depressive Disorder (MDD).

• Advancement of Lead Candidate

  The Ascend study builds on positive Phase 2b results and is aligned in design with the ongoing Emerge Phase 3 study for MDD and other trials for generalized anxiety disorder.

• Future Data Readouts

  Topline data from the Ascend study's 12-week double-blind period is anticipated in 2027, following the expected topline readout from the Emerge study in late Q2 2026.

auto_awesomeAnalysis

Definium Therapeutics has initiated its second pivotal Phase 3 study, Ascend, for DT120 ODT in Major Depressive Disorder (MDD) by dosing the first patient. This marks a significant advancement in the company's lead clinical program, building on positive Phase 2b results and complementing the ongoing Emerge Phase 3 study for MDD. Successful progression through Phase 3 is critical for potential regulatory approval and addresses a substantial unmet medical need in MDD. Investors will now look towards the anticipated topline data from the Emerge study in late Q2 2026, followed by Ascend data in 2027.